Cambridge, UK, 12th October 2021 – TRx is pleased to announce completion of a first seed investment round. Funds secured from an esteemed group of private life science specialists will enable rapid progression of TRx’s wholly-owned product pipeline, targeting the creation of first-in-class therapies in inflammatory and respiratory diseases in addition to cancer.

TRx CEO, Dr Robin Bannister said “This is a landmark moment for our young business, achieved in a short period. TRx has been highly fortunate to forge early co-development partnerships with multiple companies, each deeply committed to therapeutic innovation. TRx technology now underpins multiple programmes progressing to clinic, with the potential to provide immense benefit to our partners and ultimately their patients. We will continue to enter further co-development programmes where appropriate. However, in turn, these programmes have informed us to a great extent as to the possibilities of our platform and proceeds from this initial raise, from investors we are honoured to have joined us, allow us to commence our journey into development of our wholly owned product portfolio, which is extremely exciting.”